SLNO Quote, Financials, Valuation and Earnings

Arcutis Biotherapeutics has a net margin of -- compared to Soleno Therapeutics's net margin of -38.06%. Soleno Therapeutics's return on equity of -- beat Arcutis Biotherapeutics's return on equity of -74.7%.

Soleno Therapeutics has a consensus price target of $111.00, signalling upside risk potential of 47.86%. On the other hand Arcutis Biotherapeutics has an analysts' consensus of $21.14 which suggests that it could grow by 55.12%. Given that Arcutis Biotherapeutics has higher upside potential than Soleno Therapeutics, analysts believe Arcutis Biotherapeutics is more attractive than Soleno Therapeutics.

Soleno Therapeutics has a beta of -2.668, which suggesting that the stock is 366.818% less volatile than S&P 500. In comparison Arcutis Biotherapeutics has a beta of 1.867, suggesting its more volatile than the S&P 500 by 86.675%.

Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Arcutis Biotherapeutics pays out -- of its earnings as a dividend.

Soleno Therapeutics quarterly revenues are --, which are smaller than Arcutis Biotherapeutics quarterly revenues of $65.8M. Soleno Therapeutics's net income of -$43.8M is lower than Arcutis Biotherapeutics's net income of -$25.1M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Arcutis Biotherapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 4,092.38x versus 7.99x for Arcutis Biotherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Axsome Therapeutics has a net margin of -- compared to Soleno Therapeutics's net margin of -48.92%. Soleno Therapeutics's return on equity of -- beat Axsome Therapeutics's return on equity of -309.19%.

Soleno Therapeutics has a consensus price target of $111.00, signalling upside risk potential of 47.86%. On the other hand Axsome Therapeutics has an analysts' consensus of $176.53 which suggests that it could grow by 64.64%. Given that Axsome Therapeutics has higher upside potential than Soleno Therapeutics, analysts believe Axsome Therapeutics is more attractive than Soleno Therapeutics.

Soleno Therapeutics has a beta of -2.668, which suggesting that the stock is 366.818% less volatile than S&P 500. In comparison Axsome Therapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.356%.

Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Axsome Therapeutics pays out -- of its earnings as a dividend.

Soleno Therapeutics quarterly revenues are --, which are smaller than Axsome Therapeutics quarterly revenues of $121.5M. Soleno Therapeutics's net income of -$43.8M is higher than Axsome Therapeutics's net income of -$59.4M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Axsome Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 4,092.38x versus 11.98x for Axsome Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

BridgeBio Pharma has a net margin of -- compared to Soleno Therapeutics's net margin of -143.55%. Soleno Therapeutics's return on equity of -- beat BridgeBio Pharma's return on equity of --.

Soleno Therapeutics has a consensus price target of $111.00, signalling upside risk potential of 47.86%. On the other hand BridgeBio Pharma has an analysts' consensus of $58.78 which suggests that it could grow by 74.21%. Given that BridgeBio Pharma has higher upside potential than Soleno Therapeutics, analysts believe BridgeBio Pharma is more attractive than Soleno Therapeutics.

Soleno Therapeutics has a beta of -2.668, which suggesting that the stock is 366.818% less volatile than S&P 500. In comparison BridgeBio Pharma has a beta of 1.149, suggesting its more volatile than the S&P 500 by 14.912%.

Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. BridgeBio Pharma pays out -- of its earnings as a dividend.

Soleno Therapeutics quarterly revenues are --, which are smaller than BridgeBio Pharma quarterly revenues of $116.6M. Soleno Therapeutics's net income of -$43.8M is higher than BridgeBio Pharma's net income of -$167.4M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while BridgeBio Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 4,092.38x versus 50.03x for BridgeBio Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals has a net margin of -- compared to Soleno Therapeutics's net margin of -53.36%. Soleno Therapeutics's return on equity of -- beat Madrigal Pharmaceuticals's return on equity of -49.57%.

Soleno Therapeutics has a consensus price target of $111.00, signalling upside risk potential of 47.86%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of $421.93 which suggests that it could grow by 44.59%. Given that Soleno Therapeutics has higher upside potential than Madrigal Pharmaceuticals, analysts believe Soleno Therapeutics is more attractive than Madrigal Pharmaceuticals.

Soleno Therapeutics has a beta of -2.668, which suggesting that the stock is 366.818% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.906, suggesting its less volatile than the S&P 500 by 190.598%.

Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

Soleno Therapeutics quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals quarterly revenues of $137.3M. Soleno Therapeutics's net income of -$43.8M is higher than Madrigal Pharmaceuticals's net income of -$73.2M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 4,092.38x versus 20.04x for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.